Home    Back

Propylene glycol-free melphalan hydrochloride    (DrugBank: Melphalan, Propylene glycol)

1 disease
IDDisease name (Link within this page)Number of trials
28Systemic amyloidosis1

28. Systemic amyloidosis    [ 212 clinical trials,   234 drugs,   (DrugBank: 72 drugs),   54 drug target genes,   170 drug target pathways]
Searched query = "Systemic amyloidosis", "AL amyloidosis", "Immunoglobulin light chain amyloidosis", "Amyloid light-chain amyloidosis", "Familial amyloidosis", "Familial amyloid polyneuropathy", "Senile transthyretin amyloidosis", "Senile TTR amyloidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 212 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT02994784
(ClinicalTrials.gov)		January 8, 201818/11/2016Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis PatientsA Phase II Single-Center, Open-Label, Safety and Efficacy Study of Propylene Glycol-Free Melphalan Hydrochloride (Evomela) in AL Amyloidosis Patients Undergoing Autologous Stem Cell TransplantationAmyloidosis; SystemicDrug: Propylene Glycol-Free Melphalan HydrochlorideBoston Medical CenterSpectrum Pharmaceuticals, IncRecruiting18 YearsN/AAll43Phase 2United States